**Carlos Martin 1,2,3,\*, Nacho Aguilo 1,2, Dessislava Marinova 1,2 and Jesus Gonzalo-Asensio 1,2**


Received: 10 March 2020; Accepted: 31 March 2020; Published: 10 April 2020

**Abstract:** In addition to antibiotics, vaccination is considered among the most efficacious methods in the control and the potential eradication of infectious diseases. New safe and effective vaccines against tuberculosis (TB) could be a very important tool and are called to play a significant role in the fight against TB resistant to antimicrobials. Despite the extended use of the current TB vaccine Bacillus Calmette-Guérin (BCG), TB continues to be transmitted actively and continues to be one of the 10 most important causes of death in the world. In the last 20 years, different TB vaccines have entered clinical trials. In this paper, we review the current use of BCG and the diversity of vaccines in clinical trials and their possible indications. New TB vaccines capable of protecting against respiratory forms of the disease caused by sensitive or resistant *Mycobacterium tuberculosis* strains would be extremely useful tools helping to prevent the emergence of multi-drug resistance.

**Keywords:** BCG; tuberculosis vaccines; TBVI; EDCTP; IAVI; CTVD
